Martin Shkreli vs. Max Marchione: the great peptide debate

Summary

Martin Shkreli and Max Marchione clash over whether peptides represent a legitimate health frontier or a dangerous descent into unproven medicine.

Shkreli, a pharmaceutical veteran, dismisses the peptide craze as driven by psychological need for control and institutional distrust. He argues peptides are the weakest drug class—avoided by pharma for good reason—and that off-label use amounts to DIY drug manufacturing with no safety guarantees. His sharpest target is BPC 157, which he calls "the biggest scam I've ever seen." The peptide was developed by a Croatian researcher, has never been independently published, lacks plausible physiology given its 15-amino-acid structure and minutes-long half-life, and failed clinical trials when Pleva, a respected Balkan pharma company, licensed and tested it. Patient testimonials reflect placebo effect, Shkreli argues. Normalizing unregulated peptide injection undermines the FDA and evidence-based medicine that built American pharma.

Marchione, co-founder of Superpower, concedes he was initially skeptical but converted after speaking with dozens of doctors who prescribe peptides to their patients. The real debate is not legality versus prohibition but gray market versus white market. Millions of people are already self-injecting peptides sourced online. The question is whether to regulate and standardize these compounds through GMP-certified compounding pharmacies under FDA oversight, or leave them in the shadows where supply chains are unverifiable.

Marchione points to scale and physician confidence. Thousands of doctors have prescribed peptides for 10 to 20 years without facing license revocation. Millions of patients report life changes. His father took BPC 157 for three days and stopped needing painkillers after four months. His co-founder, off biologics for autoimmune disease after peptide use, no longer has the condition. Marchione acknowledges these are anecdotal, not randomized controlled trials, but argues real-world clinical experience from physicians with reputational and legal skin in the game carries weight.

Where they deadlock is on what counts as evidence. Shkreli insists only FDA-approved drugs or rigorous RCTs matter. Marchione counters that many now-standard therapies showed real-world benefit before formal trials proved them. GLP-1 receptor agonists—peptides themselves—are the most impactful drug class ever discovered. He also takes Thymosin alpha-1, approved in 35 countries, and credits it for immunity to COVID and flu in high-exposure situations.

Shkreli pushes back on drug class weakness. GLP-1 drugs work only because they are heavily modified by pharmaceutical chemistry beyond the naked peptide. Thymosin alpha-1's short half-life is a liability, not a feature. Marchione counters that modern science can extend peptide half-life and that the FDA itself has signaled willingness to legalize several category-two peptides with sufficient safety signals.

On intellectual property, Shkreli argues that sourcing Chinese-manufactured copies of Eli Lilly's retratrutide amounts to piracy and threatens R&D incentives. Marchione agrees that patent theft is wrong but shifts focus to regulatory capture. If a drug works in 35 countries and thousands of doctors prescribe it, why should the US FDA demand a $300 million reformulation just to capture a patentable composition?

Shkreli's closing stance: peptide use is concentrated among wealthy tech people in San Francisco and New York playing doctor because they feel a loss of control. The government's job is partly to protect people from their own poor judgment. Medicine progressed because of the capitalist system, the FDA, and rigorous trials—not Reddit forums and bathtub drug labs.

Marchione's closing: Superpower is working with biotech companies to run clinical trials on BPC 157 and other peptides. The FDA system works well for many purposes but not all. When new safety and efficacy signals emerge and gray markets proliferate, regulation must adapt. Legalizing peptides with the strongest evidence profiles reduces net harm compared to forcing patients back to painkillers or biologics while waiting decades for pharma to monetize prevention rather than disease.